

# C-Reactive Protein Concentrations Among Crop and Dairy Farmers with Stable Chronic Obstructive Pulmonary Disease

Saso Stoleski<sup>1\*</sup>, Jordan Minov<sup>1</sup>, Jovanka Karadzinska-Bislimovska<sup>1</sup>, Dragan Mijakoski<sup>1</sup>, Lutfiye Tutkun<sup>2</sup>

<sup>1</sup>Institute for Occupational Health of Republic of Macedonia - Skopje, WHO Collaborating Center, GaZlen Collaborating Center, Skopje, Republic of Macedonia; <sup>2</sup>Department of Medical Biochemistry, Yozgat, Bozok University, Faculty of Medicine, Bozok, Turkey

## Abstract

**Citation:** Stoleski S, Minov J, Karadzinska-Bislimovska J, Mijakoski D, Tutkun L. C-reactive protein concentrations among crop and dairy farmers with the stable chronic obstructive pulmonary disease. Open Access Maced J Med Sci. 2017 Oct 15; 5(6):724-729. <https://doi.org/10.3889/oamjms.2017.140>

**Keywords:** markers of inflammation; COPD; farmers; respiratory symptoms; spirometry.

**\*Correspondence:** Saso Stoleski, Center for Respiratory Functional Diagnostics, Institute for Occupational Health of R. Macedonia, WHO Collaborating Center and GaZlen Collaborating Center, II Makedonska Brigada 43, 1000 Skopje, R. Macedonia, Phone: +389 71 314 435, Fax: +389 2 2621 428. E-mail: [ssoleski@yahoo.com](mailto:ssoleski@yahoo.com)

**Received:** 21-Jun-2017; **Revised:** 30-Jul-2017;  
**Accepted:** 31-Jul-2017; **Online first:** 09-Sep-2017

**Copyright:** © 2017 Saso Stoleski, Jordan Minov, Jovanka Karadzinska-Bislimovska, Dragan Mijakoski, Lutfiye Tutkun. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

**Funding:** This research did not receive any financial support.

**Competing Interests:** The authors have declared that no competing interests exist.

**AIM:** To assess the mean serum C-reactive protein concentrations among farmers and office controls, and further examined its relation to exposure duration, smoking habit, as well as presence or absence of COPD.

**METHODS:** A cross-sectional survey was performed including examined group (EG), composed of agricultural workers (87 crop - EG1 and 83 dairy farmers - EG2), and control group (CG) composed by 80 office workers. Evaluation of subjects included a questionnaire on chronic respiratory symptoms, lung function tests, COPD diagnostics, and measurement of CRP serum concentrations.

**RESULTS:** Serum CRP concentrations were raised in stable COPD patients independent of smoking habit or exposure duration. The mean CRP serum concentrations were higher in the subjects of EG1 and EG2 compared with those in CG, but without statistical significance. This count for mean CRP serum concentrations in subjects of EG1 and EG2 exposed more than 20 years and for those in smokers in all three groups as well. The mean CRP serum concentrations were significantly higher in subjects with COPD within EG1 ( $P=0.049$ ) and EG2 ( $P=0.040$ ), while those in CG were not.

**CONCLUSION:** Data obtained suggest that systemic inflammation is present in farmers with COPD and CRP is an important biomarker in COPD in means of reflecting disease severity and prognosis of exposed farmers.

## Introduction

Chronic obstructive pulmonary disease (COPD) is a major worldwide health problem with increasing prevalence and incidence. Although cigarette smoking is the most commonly encountered risk factor for COPD worldwide, some genetic and environmental risk factors are also well-identified in the disease pathogenesis. Still, it is well-known that nonsmokers may also develop chronic airflow obstruction [1].

Chronic obstructive pulmonary disease (COPD) is a complex chronic inflammatory disease of the lungs involving several types of inflammatory cells and a variety of inflammatory mediators. The relationship between these cell types, cytokines, and the sequence of events that concludes with

progressive airflow limitation and destruction of lung parenchyma remains largely unknown [2]. Although primarily affecting the lungs, the chronic inflammatory process of COPD does have systemic repercussions. Inflammatory markers, including C-reactive protein (CRP), lipopolysaccharide binding protein, the soluble TNF transmembrane receptor 75 (sTNF-R75), and soluble adhesion molecules are increased in the systemic circulation of patients with COPD [3-5].

Systemic inflammation is determined by measurement of the CRP serum concentration and is present in patients with small airways obstruction. Sin et al. [6] reported that the withdrawal of inhaled corticosteroids resulted in a significant increase in CRP levels.

Burning wood, animal dung, crop residues and coal in open fires or improper stoves may lead to

serious indoor air pollution. The indoor air pollution resulting from crop or dairy farming is an important risk factor for COPD especially in developing countries worldwide [7]. The chronic inflammation in COPD, orchestrated by multiple inflammatory cells and mediators in the airways and the lung tissues, is induced by inhalation of noxious gases and particulate matter. This persistent inflammatory response in the lung is also associated with a significant systemic inflammatory response yielding adverse clinical outcomes, so-called systemic effects of COPD [8]. Although the origin of systemic inflammation present in COPD remains poorly understood, and correlations in the regulation of inflammation in the pulmonary and systemic compartments are not well-documented yet, it is established that some inflammatory markers are risen in systemic circulation [8,9]. Of the blood-based biomarkers, C-reactive protein (CRP) has shown the greatest promise [10]. In COPD patients increased CRP levels are associated with poor lung function, reduced exercise capacity and worse quality of life as well as being a significant predictor of all-cause mortality [11-14]. As well as COPD itself, smoking, which is the most commonly encountered risk factor for the disease is also responsible for the rise in serum CRP levels [15]. Though to our knowledge the effect of crop and dairy farming exposure, potentially initiating the inflammatory process in the lungs of COPD patients, on serum CRP levels has not been studied in our setting previously. The growing awareness of COPD is a complex disease involving several organs with an established low-grade systemic inflammation, biomarkers have been more focus of interest in clarifying the pathogenesis and progression of COPD as well as in designing new therapeutic targets and models for the disease [14]. Based on the current knowledge that COPD is a multicomponent systemic disease with elevated serum CRP levels and that smoking itself leads to rising in CRP levels, the present study was undertaken. With the study, the authors aim to determine the relationship between serum CRP levels and well-known clinical parameters in COPD considering the impact of smoking behaviour, farming exposure duration and its characteristics.

In the actual study we have assessed the mean CRP serum concentrations among crop and dairy farmers and office controls, and further examined its relation to exposure duration, smoking habit, as well as presence or absence of COPD.

## Subjects and Methods

### *Study design and setting*

We have performed a cross-sectional research in the Center for Respiratory Functional

Diagnostics at the Institute for Occupational Health of Republic of Macedonia, Skopje - WHO Collaborating Center for Occupational Health and GA2LEN Collaborating Center within the period September 2014 and April 2015.

### **Subjects**

The survey included workers employed at agricultural enterprise divided into two groups: examined group (EG), composed of agricultural workers (crop and dairy farmers), and control group (CG) composed by office workers within the same enterprise.

EG consists of 170 subjects, while CG has 80 examinees. For the study purposes, and depending on the main agricultural activity, subjects were divided into two groups, examined group 1 (EG1) and examined group 2 (EG2).

EG1 comprised 87 crop farmers (mean age =  $53.4 \pm 7.8$  years) engaged in crop farming (mean duration of exposure  $22.9 \pm 7.8$  years) with main activities composed of cultivating crops and vegetables, planting, digging, use of mechanized equipment, irrigation, and pesticide handling. They were exposed to various respiratory agents: dust, inappropriate climate, fumes, vapours and pesticides.

EG2 consists of 83 dairy farmers (mean age =  $52.6 \pm 8.7$  years) employed as dairy farmers (mean duration of exposure  $23.7 \pm 7.6$  years), working inside confinement buildings, and exposed to: dust, inappropriate microclimate conditions, chemical hazards, vapors, gases, heavy manual work, animal contact, unfavorable body positions, and repetitive hand movements. Their main occupational activities were: preparation of fodder feeding and animal meals, milking, staying in the barn, preparation of straw, and hay making, cattle rising, as well as taking care of milk hygiene and animal health. Also, a similar group of 80 office workers (mean age =  $52.7 \pm 8.2$  years) with no exposure to respiratory agents, matched for age, duration of employment, daily smoking and socioeconomic status was studied as a control.

The Institute's ethics committee has approved the content of our study protocol, whereas each examined subject was informed and gave written consent before any involvement in the study.

### **Questionnaire**

All study subjects were interviewed by the standardized questionnaire, including questions on work history, respiratory symptoms in the last 12 months, and smoking habit.

Chronic respiratory symptoms in the last 12 months (a cough, phlegm, dyspnea, wheezing, and chest tightness) were obtained using the European

Community for Coal and Steel questionnaire (ECCS-87), and the European Community Respiratory Health Survey (ECRHS) questionnaire [16, 17].

Classification of smoking status was done according to the World Health Organization (WHO) guidelines on definitions of smoking status [18].

Daily smoker was defined as a subject who smoked at the time of the field survey at least once a day, except on days of religious fasting. Among daily smokers, lifetime cigarette smoking and the daily mean of cigarettes smoked were also assessed. Pack-years smoked were calculated according to the actual recommendations [19]. Ex-smoker was defined as a formerly daily smoker, no longer smokes.

Passive smoking or exposure to environmental tobacco smoke (ETS) was defined as the exposure of a person to tobacco combustion products from smoking by others [20].

### Spirometry

All study subjects underwent spirometry testing, performed by spirometer Ganshorn SanoScope LF8 (Ganshorn Medizin Electronic GmbH, Germany), measuring forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC ratio, and maximal expiratory flow at 50%, 75%, and 25-75% of FVC (MEF50, MEF75, and MEF25-75, respectively), by recording the best result from three measurements of the values of FEV1 within 5% of each other. The results were expressed as percentages of the predicted values according to the European Community for Coal and Steel (ECCS) norms [21].

### Diagnostic criteria for COPD

According to the actual recommendations by Global Initiative for Chronic Obstructive Lung Disease (GOLD), COPD is defined by post-bronchodilator FEV1/FVC ratio lower than 0.70 in subjects with dyspnea, chronic cough and/or a cough with phlegm [22]. Measurement of CRP serum concentrations as markers of inflammation. Mean CRP serum concentrations are measured by chemiluminescent immunoassay method with Immulite 1000 in subjects with chronic respiratory symptoms and/or spirometric impairment. CRP serum concentrations < 5 mg/L are within the normal range [23].

### Statistical analysis

We have analyzed the data using Statistica for Windows version 7. Continuous variables were expressed as mean values with standard deviation and categorical variables as numbers and percentages. The comparison of mean CRP serum concentrations was performed by independent-

samples T-test. A P-value of less than 0.05 was considered statistically significant.

## Results

Table 1 gives an overview of the demographic and overall characteristics of the subjects within the examined and control groups.

**Table 1: Demographic and overall characteristics of the study subjects**

Variable	EG1 (n = 87)	EG2 (n = 83)	CG (n = 80)
Gender / M/F ratio	3.6	2.6	2.7
Age / years	53.4 ± 7.8	52.6 ± 8.7	52.7 ± 8.2
BMI / kg m <sup>2</sup>	25.1 ± 3.5	25.4 ± 3.6	26.2 ± 3.7
Duration of employment / years	29.2 ± 8.9	26.3 ± 10.1	25.3 ± 9.8
Exposure duration / years	22.9 ± 7.8	23.7 ± 7.6	/
Active (daily) smokers	45 (51.7%)	39 (46.9%)	39 (48.7%)
Smoking experience / years	19.7 ± 8.1	18.9 ± 7.6	19.2 ± 7.8
Cigarettes / day	15.4 ± 7.3	14.6 ± 6.8	14.8 ± 7.2
Ex-smokers	12 (13.8%)	9 (10.8%)	12 (15%)
Passive smokers	11 (12.6%)	8 (9.6%)	7 (8.7%)

Numerical data are expressed as mean values with standard deviations; frequencies of active, passive, and ex-smokers are given as number and percent of subjects with certain variable. M: males; F: females; BMI: body mass index.

Table 2 shows the frequencies of COPD symptoms (dyspnea, chronic cough and phlegm) negative BD tests, post-bronchodilator FEV1/FVC less than 0.70 and frequency of COPD in subjects of EG1, EG2 and CG.

**Table 2: Frequency of COPD symptoms, negative BD tests, post-bronchodilator FEV<sub>1</sub>/FVC less than 0.70 and COPD in subjects of EG1, EG2 and CG**

Variable	EG1 (n = 87)	EG2 (n = 83)	CG (n = 80)
Respiratory symptoms within the last 12 months	23 (26.4%)	24 (28.9%)	15 (18.8%)
Negative BD test	11 (12.6%)	9 (10.8%)	5 (6.3%)
Post-bronchodilator test FEV <sub>1</sub> /FVC < 0.70	7 (8.1%)	8 (9.6%)	4 (5%)
COPD	6 (6.9%)	7 (8.4%)	3 (3.8%)

Data are given as number and percent of subjects with a certain variable.

For the study purposes, we have examined the marker of chronic inflammation - CRP (C-reactive protein) among subjects in the three groups having one or more chronic respiratory symptoms and/or spirometric impairments.

### CRP serum concentrations

The mean CRP serum concentrations were higher in EG1 compared to CG, but without statistical significance (Table 3).

**Table 3: Mean CRP serum concentrations in subjects of EG1 and CG**

	EG1 (n = 35)	CG (n = 15)	P-value*
CRP (mg/L)	3.5 ± 2.4	3.1 ± 2.2	0.590

Data are given as means with standard deviation. \*Tested with t-test for independent samples.

The mean CRP serum concentrations were higher in EG2 compared to CG, but statistical significance was not yet reached (Table 4).

**Table 4: Mean CRP serum concentrations in subjects of EG2 and CG**

	EG2 (n = 32)	CG (n = 15)	P-value*
CRP (mg/L)	3.6 ± 2.8	3.1 ± 2.2	0.529

Data are given as means with standard deviation. \*Tested with t-test for independent samples.

Table 5 shows the mean CRP serum concentrations in subjects of EG1 with exposure duration less or equal to 20 years and over 20 years.

**Table 5: Mean CRP serum concentrations in subjects of EG1 according to job exposure duration**

	Exposed > 20 years (n = 24)	Exposed ≤ 20 years (n = 11)	P-value*
CRP (mg/L)	3.7 ± 2.8	3.2 ± 2.2	0.646

Data are given as means with standard deviation. \* Tested with t-test for independent samples.

The mean CRP serum concentrations were higher in subjects of EG1 exposed longer than 20 years, compared to those exposed less than 20 years, but without statistical significance.

**Table 6: Mean CRP serum concentrations in subjects of EG2 according to job exposure duration**

	Exposed > 20 years (n = 22)	Exposed ≤ 20 years (n = 10)	P-value*
CRP (mg/L)	3.9 ± 2.9	3.4 ± 2.2	0.653

Data are given as means with standard deviation. \*Tested with t-test for independent samples.

Table 6 gives an overview of mean CRP serum concentrations in subjects of EG2 with duration of exposure less or equal to 20 years and over 20 years. The mean CRP serum concentrations were non-significantly higher in subjects of EG2 exposed longer than 20 years, compared to those exposed less than 20 years. The mean CRP serum concentrations in subjects of all three groups depending on the smoking habit are given in Table 7.

**Table 7: Mean CRP serum concentrations in subjects of EG1, EG2, and CG depending on smoking habit**

Variable	EG1 (n = 35) 21 vs 14	P*	EG2 (n = 32) 19 vs 13	P*	CG (n = 15) Nine vs 6	P*
CRP in active smokers	3.71 ± 2.6	NS	3.9 ± 3.1	NS	2.9 ± 2.1	NS
CRP in non-smokers	3.3 ± 2.1	0.705	3.4 ± 2.3	0.613	3.3 ± 2.7	0.708

Data are given as means with standard deviation. \* Tested with t-test for independent samples.

The mean CRP serum concentrations were higher in smokers within the three groups, but without significant difference between smokers and non-smokers. Mean CRP serum concentrations in all three groups due to the presence or absence of COPD are shown in Table 8.

**Table 8: Mean CRP concentrations in subjects of EG1, EG2, and CG due to the presence or absence of COPD**

Variable	EG1 (n = 35) Six vs 29	P*	EG2 (n = 32) Seven vs 25	P*	CG (n = 15) Three vs 12	P*
CRP in subjects with COPD	6.5 ± 4.9	0.049	6.8 ± 4.9	0.040	5.9 ± 3.9	0.117
CRP in subjects without COPD	3.5 ± 2.8		3.6 ± 2.9		3.1 ± 2.3	

Data are given as means with standard deviation. \*Tested with t-test for independent samples.

The mean CRP serum concentrations were significantly higher in subjects with COPD within EG1 and EG2, while those within CG are not.

## Discussion

In the actual research within the subjects of all three groups having one or more chronic respiratory symptoms and spirometric impairment, we have measured CRP as a marker of chronic inflammation. The main finding of the present study is that CRP levels were raised in stable COPD patients independent of smoking habit or exposure duration. The mean CRP serum concentrations were higher in the subjects of EG1 and EG2 compared with those in CG, but without reaching statistical significance. This count for mean CRP serum concentrations in subjects of EG1 and EG2 exposed more than 20 years and for those in smokers in all three groups as well. The mean CRP serum concentrations were significantly higher in subjects with COPD within EG1 and EG2, while those in CG were not. This finding is by the results of many studies on COPD and markers of chronic inflammation within the general population, but also in certain groups of exposed workers. Aksu et al. reported a significantly higher CRP serum levels among subjects in the rural areas of Turkey exposed to biomass fuels [7], compared with the control group. The study by Pinto-Plata et al. did not find a correlation between CRP serum levels and smoking, while it significantly decreases in subjects on continuous therapy with inhaled corticosteroids [13].

Several studies on COPD have demonstrated an influx of immune cells, both in the airway wall and lumen, the alveoli and pulmonary vessels [24]. Disease severity is associated with increased airways inflammation [25]. Many studies have shown that COPD patients have higher levels of some inflammatory markers in blood, notably C-reactive protein (CRP) [26–29], fibrinogen [30], and the inflammatory cytokines interleukin (IL)-6 [29, 31] and IL-8 [32, 33], respectively. For tumour necrosis factor (TNF) results are conflicting, as some studies [31, 34] have found higher TNF-α levels among COPD patients, whereas some studies have not [31, 35]. It has been suggested that systemic inflammation may explain part of the heterogeneity of COPD phenotypes, such as loss of lean body mass [36], and

the higher prevalence of co-morbid disorders such as coronary heart disease, depression and hypertension [37, 38].

Elevated serum CRP levels indicating a low grade persistent systemic inflammation in COPD patients was first described in early 2000's [39, 40]. Then the positive relationship between CRP levels and important prognostic clinical variables in stable COPD patients was reported in 2006 by de Torres et al. [11]. These results indicate that systemic inflammation is related to the disease severity and physiological parameters should be considered in evaluating the COPD patients instead of focusing only on lung function indices. The airflow limitation in COPD is associated with the abnormal inflammatory response of the lung to noxious particles or gases. Farming exposure to noxious respiratory particles remains still a burning issue in most countries, independently of the degree of economic growth and preventive equipment used. Cigarette smoking, on the other hand, is still the most commonly encountered risk factor [41]. It is probable that such as in the case of smoking, exposure in farming also disturbs the cellular oxidant-antioxidant balance and initiates the inflammatory process in the lungs of COPD patients. To our knowledge, the effect of such exposure on serum CRP levels has not been studied previously. As mentioned above, in the present study no significant difference in serum CRP concentrations was detected between the subjects grouped according to smoking status and to farming exposure duration. About these findings, we confirm that elevated CRP concentrations in subjects with COPD were due to the ongoing inflammatory status and are independent of the smoking habit or farming exposure. High CRP levels have been shown to be associated with all-cause, cardiovascular, and cancer specific causes of mortality [39] thus reflect poor prognosis in COPD patients. Opposed to some previous reports, declaring that the use of inhaled corticosteroids decreases serum CRP levels [6, 13], our study was unable to confirm any significant difference in serum CRP concentrations between subjects with COPD who were on inhaled corticosteroid therapy and those who were not. This is not surprising since the recent reports came along denying any reduction in systemic inflammation in COPD with the use of inhaled corticosteroids [42, 43].

Our present study has some limitations. Namely, relatively small number of the subjects in the study groups may be a limitation, with possible implications on the data obtained and its interpretation, especially in their possible interpolation on the population level for the agricultural workers in R. Macedonia. Also, there is a lack of ambient monitoring and exposure measurement (endotoxin, dust, gases, vapours, and chemicals) in this survey, but the data are based on specially designed questionnaire and job exposure matrices, which were introduced in our country.

Finally, we can conclude that systemic inflammation is present in farmers with COPD and CRP is an important biomarker in COPD in means of reflecting disease severity and prognosis of exposed farmers. Serum CRP levels were raised independently of smoking status and farming exposure duration in COPD patients reflecting that CRP rise was a result of the inflammatory nature of the disease itself. Further trials must be performed to investigate this relationship, but also having in mind exposure duration and its characteristics in farming, as well.

## References

1. Barnes PJ. Medical progress: chronic obstructive pulmonary disease. *N Engl J Med.* 2000;343:269-80. <https://doi.org/10.1056/NEJM200007273430407> PMID:10911010
2. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. *Eur Respir J.* 2003;22:672-88. <https://doi.org/10.1183/09031936.03.00040703> PMID:14582923
3. Vernooij JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2002;166:1218-24. <https://doi.org/10.1164/rccm.2202023> PMID:12403691
4. Noguera A, Busquets X, Sauleda J, et al. Expression of adhesions molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 1998;158:1664-8. <https://doi.org/10.1164/ajrccm.158.5.9712092> PMID:9817722
5. Aaron et al. Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. *Respiratory Research.* 2010;11:41. <https://doi.org/10.1186/1465-9921-11-41> PMID:20412595 PMCid:PMC2874769
6. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systematic markers of inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2004;170:760-5. <https://doi.org/10.1164/rccm.200404-543OC> PMID:15229100
7. Aksu F, Çapan N, Aksu K, Ofluoğlu R, Canbakan S, Yavuz B, Akin KO. C-reactive protein levels are raised in stable Chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure. *J Thorac Dis.* 2013;5(4):414-421. PMID:23991296 PMCid:PMC3755654
8. Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). *Proc Am Thorac Soc.* 2007;4:522-5. <https://doi.org/10.1513/pats.200701-004FM> PMID:17878464
9. Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. *Proc Am Thorac Soc.* 2005;2:26-33. <https://doi.org/10.1513/pats.200408-039MS> PMID:16113466
10. Sin DD, Man SF. Biomarkers in COPD: are we there yet? *Chest.* 2008;133:1296-8. <https://doi.org/10.1378/chest.08-0455> PMID:18574284
11. de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. *Eur Respir J.* 2006;27:902-7. PMID:16455829
12. Broekhuizen R, Wouters EF, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. *Thorax.* 2006;61:17-22. <https://doi.org/10.1136/thx.2005.041996> PMID:16055618 PMCid:PMC2080712
13. Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein

- in patients with COPD, control smokers and non-smokers. *Thorax*. 2006;61:23-8. <https://doi.org/10.1136/thx.2005.042200> PMID:16143583 PMCID:PMC2080714
14. Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. *Thorax*. 2006;61:849-53. <https://doi.org/10.1136/thx.2006.059808> PMID:16738034 PMCID:PMC2104755
15. Danesh J, Muir J, Wong YK, et al. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. *Eur Heart J*. 1999;20:954-9. <https://doi.org/10.1053/euhj.1998.1309> PMID:10361047
16. Minette A. Questionnaire of the European Community for Coal and Steel (ECSC) on respiratory symptoms. 1987 - Updating of the 1962 and 1967 questionnaires for studying chronic bronchitis and emphysema. *Eur Respir J*. 1989;2:165-177. PMID:2703044
17. European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Respiratory Health Survey (ECRHS). *Eur Respir J*. 1996;9:687-695. <https://doi.org/10.1183/09031936.96.09040687>
18. World Health Organization. Guidelines for controlling and monitoring the tobacco epidemic. Geneva: WHO, 1998.
19. Smoking Pack-Years. Available from: <http://smokingpackyears.cm/calculate>. Accessed 15 June 2017.
20. US Department of Health and Human Services. The health consequences of smoking: chronic obstructive pulmonary disease. A report of the Surgeon General. US Department of Health and Human Services, Public Health Service, Office of the Assistant for Health, Office of Smoking and Health. DHHS Publication No. 84-50 205,1984.
21. Quajner PhH, ed. Standardization of Lung Function Tests - 1993 Update. Report Working Party for the European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J*. 1993;16(l):1-100.
22. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2017 Update. Available at: <http://www.goldcopd.org/>.
23. Roberts LW, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of Four Automated High-Sensitivity C-Reactive Protein Methods: Implications for Clinical and Epidemiological Applications. *Clinical Chemistry*. 2000;46(4):461-468. PMID:10759469
24. O'Donnell R, Breen D, Wilson S, et al. Inflammatory cells in the airways in COPD. *Thorax*. 2006;61:448-454. <https://doi.org/10.1136/thx.2004.024463> PMID:16648353 PMCID:PMC2111192
25. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med*. 2004;350:2645-2653. <https://doi.org/10.1056/NEJMoa032158> PMID:15215480
26. Broekhuizen R, Grimble RF, Howell WM, et al. Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1b - 511 single nucleotide polymorphism. *Am J Clin Nutr*. 2005;82:1059-1064. PMID:16280439
27. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. *Am J Med*. 2003;114:758-762. [https://doi.org/10.1016/S0002-9343\(03\)00185-2](https://doi.org/10.1016/S0002-9343(03)00185-2)
28. Yanbaeva DG, Dentener MA, Spruit MA, et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. *BMC Med Genet*. 2009;10:23. <https://doi.org/10.1186/1471-2350-10-23> PMID:19272152 PMCID:PMC2660301
29. Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. *Thorax*. 2006;61:10-16. <https://doi.org/10.1136/thx.2004.034181> PMID:16284220 PMCID:PMC2080698
30. Dahl M, Tybjaerg-Hansen A, Vestbo J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2001;164:1008-1011. <https://doi.org/10.1164/ajrccm.164.6.2010067> PMID:11587987
31. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2004;170:1286-1293. <https://doi.org/10.1164/rccm.200406-754OC> PMID:15374843
32. Piehl-Aulin K, Jones I, Lindvall B, et al. Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease. *Respiration*. 2009;78:191-196. <https://doi.org/10.1159/000207793> PMID:19270439
33. Schols AM, Buurman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. *Thorax*. 1996;51:819-824. <https://doi.org/10.1136/thx.51.8.819> PMID:8795671 PMCID:PMC472555
34. Itoh T, Nagaya N, Yoshikawa M, et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2004;170:879-882. <https://doi.org/10.1164/rccm.200310-1404OC> PMID:15271696
35. Shin KC, Chung JH, Lee KH. Effects of TNF-a and leptin on weight loss in patients with stable chronic obstructive pulmonary disease. *Korean J Intern Med*. 2007;22:249-255. <https://doi.org/10.3904/kjim.2007.22.4.249> PMID:18309683 PMCID:PMC2687660
36. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. *Eur Respir J*. 2008;31:492-501. <https://doi.org/10.1183/09031936.00074807> PMID:18310396
37. Schane RE, Woodruff PG, Dinno A, et al. Prevalence and risk factors for depressive symptoms in persons with chronic obstructive pulmonary disease. *J Gen Intern Med*. 2008;23:1757-1762. <https://doi.org/10.1007/s11606-008-0749-z> PMID:18690488 PMCID:PMC2585678
38. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. *Chest*. 2005;128:2099-2107. <https://doi.org/10.1378/chest.128.4.2099> PMID:16236861
39. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. *Circulation*. 2003;107:1514-9. <https://doi.org/10.1161/01.CIR.0000056767.69054.B3>
40. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. *Am J Med*. 2003;114:758-62. [https://doi.org/10.1016/S0002-9343\(03\)00185-2](https://doi.org/10.1016/S0002-9343(03)00185-2)
41. Kocabas A, Hancioglu A, Turkylmaz S, et al. Prevalence of COPD in Adana, Turkey (BOLD-Turkey Study). *Proc Ame Thorac Soc*. 2006;3:A543.
42. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2008;177:1207-14. <https://doi.org/10.1164/rccm.200709-1356OC> PMID:18310480
43. Miniati M, Monti S, Bottai M, et al. Prognostic value of C-reactive protein in chronic obstructive pulmonary disease. *Intern Emerg Med*. 2011;6:423-30. <https://doi.org/10.1007/s11739-011-0520-z> PMID:21249472